 |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
Recent Oncology Project Experience
| Drug |
Phase |
Description |
US Sites |
Ex-US Sites |
Patients |
Enrollment | Involvement* |
| Anti-metabolite |
I |
Combination Therapy in Relapsed Ovarian Cancer |
8 |
0 |
54 |
Ongoing | PM + MON + DM + STAT + MW |
| Bispecific Ab |
I |
Advanced Carcinomas |
3 |
0 |
48 |
Complete | PM + MON + DM + STAT + MW |
| Monoclonal Antibody |
I |
Ovarian Cancer |
3 |
0 |
30 |
Enrollment as planned | PM + MON + DM + STAT + MW |
| Small molecule proteasome inhibitor (1) |
I |
Solid tumors in treatment naive patients |
2 |
0 |
50 |
Enrollment completed in advance of schedule | PM + MON |
| Galectin-3 RA |
I |
Solid Tumors DLT |
1 |
0 |
34 |
Complete. Enrolled precisely on schedule | PM + MON + DM + STAT + MW |
| Proteasome inhibitor |
I |
Advanced cancer |
1 |
0 |
33 |
Enrollment completed as required for dose-ranging study | PM + MON + DM + STAT |
| Liposomal Anti-Neoplastic |
I |
Acute Promyelocytic Leukemia (APL) |
1 |
0 |
12 |
Complete | PM + MON + DM + STAT + MW |
| Protein Inhibitor |
I |
Hematological Malignancies |
Complete |
MW | |||
| Anti-sense |
I/II |
Chronic CLL |
4 |
6 |
50 |
Enrollment completed on schedule | PM + MON + DM + STAT + MW |
| AntiSense |
I/II |
NSCLC | Complete | MW | |||
| AntiSense |
I/II |
Colorectal Cancer |
Complete | MW | |||
| Prevention of Ca Treatment Sequelae |
II |
NSCLC |
50 |
0 |
500 |
Discontinued | PM + MON + DM + STAT + MW |
| Proteasome inhibitor (1) |
II |
Multiple myeloma in refractory patients |
12 |
0 |
100 |
Enrollment completed in advance of schedule | PM + MON |
| Galectin-3 RA |
II |
Pancreatic Cancer Combination Therapy |
10 |
0 |
52 |
Complete | PM + MON + DM + STAT + MW |
| Liposomal Anti-Neoplastic |
II |
Acute Promyelocytic Leukemia (APL) |
6 |
0 |
50 |
Complete | PM + MON + DM + STAT + MW |
| Monoclonal Ab |
II |
Non-Hodgkin's Lymphoma |
Complete | MW | |||
| Monoclonal Ab |
II |
Non-Hodgkin's Lymphoma |
Complete | MW | |||
| Monoclonal Ab |
II |
Non-Hodgkin's Lymphoma |
Complete | MW | |||
| Monoclonal Ab |
II |
Non-Hodgkin's Lymphoma |
Complete | MW | |||
| Monoclonal Ab |
II |
Solid Tumors: NSCLC & Breast Cancer |
Complete | MW | |||
| AntiSense |
II |
Breast Cancer |
Complete | MW | |||
| AntiSense |
II |
Breast Cancer |
Complete | MW | |||
| Monoclonal Ab |
II/III |
Hematological Malignancies |
50 |
0 |
150 |
Complete | PM + DM + STAT + MW |
| Galectin-3 RA |
IIb |
Colorectal Cancer |
7 |
0 |
24 |
Complete | PM + DM + STAT + MW |
| Galectin-3 RA |
IIb |
Pancreatic Cancer |
7 |
0 |
23 |
Complete | PM + DM + STAT + MW |
| Muscarinic Agonist (1) |
III |
Supportive Therapy in patients with H/N cancer |
48 |
0 |
284 |
Complete | PM + MON + DM + STAT + MW |
| Muscarinic Agonist (2) |
III |
Supportive therapy in patients with H/N cancer |
42 |
0 |
286 |
Complete | PM + MON + DM + STAT + MW |
| Cell Stimulating Factor |
III |
Supportive therapy in patients with advanced NSCLC |
30 |
0 |
300 |
Beardsworth rescued trial from another CRO; enrollment rates doubled | PM + MON + DM + STAT + MW |
| Muscarinic Agonist (4) |
III |
Supportive therapy in patients with H/N cancer |
24 |
0 |
255 |
Complete | PM + MON + DM + STAT + MW |
| Monoclonal Antibody |
III |
Ovarian Cancer |
20 |
3 |
55 |
Complete | PM + MON + DM + STAT + MW |
| Proteasome inhibitor (2) |
III |
Multiple myeloma in relapsed refractory patients |
13 |
0 |
100 |
Enrollment completed in advance of schedule | PM + MON |
| Antisense |
III |
CLL |
4 |
0 |
40 |
Complete | PM + MON + DM + STAT |
| Muscarinic Agonist (3) |
III |
Supportive therapy in patients with GvHD post BMT for hematological malignancy |
3 |
0 |
50 |
Discontinued | PM + MON + DM + STAT + MW |
| AntiSense |
III |
Prostate | Complete | MW | |||
| AntiSense |
III |
NSCLC | Complete | MW | |||
| Cytotoxic Agent |
III |
Solid Tumors |
Complete | MW | |||
| Adjunct to various Ca Therapies |
IIIb |
Various Cancers |
14 |
3 |
330 |
Complete | PM + MON + DM + STAT |
| Adjunct Therapy post BMT |
IIIb |
Patients with GvHD post BMT for Leukemia |
12 |
0 |
100 |
Complete | PM + MON + DM + STAT + MW |
| Monoclonal Ab; Adjunct Therapy post BMT in Patients with Hematological Malignancies |
IIIb |
Patients with GvHD - Prospective Trial |
5 |
0 |
97 |
Complete | PM + MON + DM + STAT + MW |
| Monoclonal Ab; Adjunct Therapy post BMT in Patients with Hematological Malignancies |
IIIb |
Patients with GvHD - Retrospective Data Collection |
2 |
0 |
54 |
Discontinued | PM + MON + DM + STAT + MW |
| AntiSense |
IIIb |
Melanoma |
Complete | MW | |||
| Cell Stimulating Factor |
IIIb/IV |
Anemia in Non-myeloid Cancers |
40 |
0 |
200 |
Complete | PM + MON + DM + STAT + MW |
| Cell Stimulating Factor |
IIIb/IV |
Anemia in Non-myeloid Cancers |
10 |
0 |
60 |
Complete | PM + MON + DM + STAT + MW |
| Cell Stimulating Factor |
IIIb/IV |
Anemia in Non-myeloid Cancers |
10 |
0 |
40 |
Complete | PM + MON + DM + STAT + MW |
| Cytotoxic Agent |
IIIb-IV |
NSCLC |
50 |
0 |
500 |
Discontinued | PM + MON + DM + STAT + MW |
| Cytotoxic Agent |
IV |
NSCLC |
2 |
0 |
24 |
Complete | PM + MON + DM |
|
Recent Cancer Projects: |
46 |
494 |
12 |
3985 |
|||
 | Oncology Overview |
| Oncology Leadership |
| Oncology Expertise |
| Oncology Projects |
| Oncology Services |
| Patient Enrollment |
| Investigators/Sites |
| Case Studies |
The Path Logo is a trademark of Beardsworth Consulting Group, Inc.